Fisetin Senolytic Reduction of Atrial Arrhythmia Susceptibility

Evidence boundary: Preclinical (aged rabbit) + associative human tissue data. No RCT for AF indication. Supplement doses likely below studied cardiac dose. Route of administration in key study is undisclosed — critical dose translation gap.

TL;DR

Fisetin, a natural flavonol, reduced induced atrial fibrillation (AF) in aged rabbits by selectively eliminating senescent atrial cells. No human clinical trial data exist for this specific indication. Wearable AF burden monitoring is the most actionable Vitals angle, but requires human clinical oversight.

Index Study

PMID 41513056 / PMC13075518 — Sengun et al., Heart Rhythm, 2026 (Brown University)

  • Aged rabbit atria (≥4 years), fisetin 20 mg/kg × 2 cycles
  • Inducible AF: 100% → 20%; Spontaneous AF: 40% → 0%
  • Reentry activity decreased; no contractile impairment
  • Human arm (n=265): SASP genes correlated with LA diameter; SA-β-Gal+ counts NOT significantly different AF vs non-AF

Evidence Grades

ClaimGrade
Fisetin has senolytic activityConfirmed
Reduces inducible AF in aged rabbitsSupported
Preserves contractile functionSupported
Human RCT for AF indicationGap
Long-term cardiac senolytic safetyGap

Vitals Angle

Wearable monitoring (investigational):

  • HRV trends, AF burden, atrial run frequency via Oura/Whoop/Apple Watch
  • 1/3/6-month post-senolytic surveillance protocol
  • SASP biomarker panel as senolytic efficacy proxy
  • Human signoff required before protocol recommendation

Key Unknowns

  • Route of administration in Brown study (oral vs IP — undisclosed)
  • Human dose equivalence unestablished
  • Established vs preventive AF effect unknown
  • No comparison to standard AF care

Source

  • Batch: batch-117-2026-04-24
  • Monograph: skills/knowledge-base/fisetin-atrial-fibrillation-senolytic/fisetin-atrial-fibrillation-senolytic.md
  • Claim Registry: skills/knowledge-base/fisetin-atrial-fibrillation-senolytic/CLAIM-REGISTRY.md